Current challenges in HER2-positive breast cancer

Fabio Puglisi, Caterina Fontanella, Vito Amoroso, Giulia Valeria Bianchi, Giancarlo Bisagni, Cristina Falci, Andrea Fontana, Daniele Generali, L. Gianni, Antonino Grassadonia, Luca Moscetti, Ilaria Portarena, Emanuela Rossi, Paolo Marchetti

Research output: Contribution to journalArticlepeer-review


The introduction of trastuzumab into routine clinical practice has had a dramatic effect on the outlook for patients with HER2-positive breast cancer. Nevertheless, answers to some long unresolved questions about the optimal use of trastuzumab (such as its role in small tumors or low-risk disease, cardiac safety in the elderly, and treatment duration) have emerged only relatively recently. Moreover, with the availability of new highly effective HER2-directed therapies, including pertuzumab and trastuzumab-emtansine (T-DM1), the treatment algorithm for HER2-positive breast cancer continues to evolve.This review provides a summary of the latest evidence providing insight into the management of early and advanced HER2-positive breast cancer and delineates future perspectives of study and treatment for these patients.

Original languageEnglish
Pages (from-to)211-221
Number of pages11
JournalCritical Reviews in Oncology/Hematology
Publication statusPublished - Feb 1 2016


  • Breast cancer
  • Dual targeting
  • HER2
  • Lapatinib
  • Neoadjuvant
  • Pertuzumab
  • Trastuzumab
  • Trastuzumab-emtansine

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology


Dive into the research topics of 'Current challenges in HER2-positive breast cancer'. Together they form a unique fingerprint.

Cite this